Skip to main content
Skip to section navigation
Skip to footer
Top
INVESTORS
Home
Investors
Contact
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR
®
Collaborations
Pipeline
Overview
LP100
|
LP184
|
LP284
|
LP300
| ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board of Directors
Advisors
Join Us
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
Contact
Investors
Press Releases
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Presentations
Media Coverage
Email Alerts
Company Info
Overview
Management Team
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Board Diversity
Year
All Years
2022
2021
2020
2019
2018
2017
2016
Category
All Releases
Financial Releases
Aug 05, 2016 10:54pm EDT
Lantern Pharma Announces Transaction to Evaluate BioNumerik’s Tavocept®
Previous Page
arrow_back
Page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
Page
10
rss_feed
News RSS
Email Alerts
Company Profile
Contacts
RSS News Feed
Join our Mailing List to get the latest Lantern news, sent right to your inbox
We're sorry
, but this form has spam protection that requires JavaScript to be enabled to work correctly. If you'd like to contact us via this form, please
enable scripts in your browser
and reload the page.
First Name
Last Name
Email Address
Sign me up for:
All Press Releases
Subscribe
This site is protected by hCaptcha and its
Privacy Policy
and
Terms of Service
apply.
Never spam. Unsubscribe anytime.
Tweets by LanternPharma
